background
antivir
effect
antiinfluenza
drug
zanamivir
may
demonstr
patient
increas
rate
declin
viral
load
time
cours
treatment
compar
placebo
histor
measur
use
plaqu
assay
cultur
enhanc
enzym
link
immunosorb
assay
ceelisa
object
develop
characteris
real
time
quantit
pcr
qpcr
assay
measur
influenza
b
viral
load
clinic
sampl
offer
improv
exist
method
particular
viru
infect
assay
studi
design
dynam
rang
robust
establish
real
time
qpcr
assay
along
stabil
assay
compon
cross
valid
real
time
pcr
assay
ceelisa
perform
parallel
test
serial
dilut
three
differ
subtyp
cultur
viru
panel
influenza
posit
throat
swab
specimen
result
assay
specif
influenza
b
dynam
rang
least
seven
log
assay
variabl
within
accept
limit
increas
toward
lower
limit
quantif
log
viral
cdna
copiesml
viru
transport
medium
ten
viral
rna
copiespcr
compon
assay
robust
enough
withstand
extend
storag
sever
freezethaw
cycl
real
time
pcr
assay
limit
quantif
equival
viru
infect
cut
equat
increas
sensit
conclus
well
characteris
real
time
pcr
assay
offer
signific
improv
exist
method
measur
viral
load
strain
influenza
b
clinic
specimen
influenza
acut
normal
selflimit
respiratori
diseas
caus
influenza
viru
result
consider
morbid
lost
work
day
patient
group
elderli
immunocompromis
underli
chronic
condit
asthma
chronic
obstruct
pulmonari
diseas
copd
vulner
complic
result
mortal
influenza
viru
envelop
singl
strand
rna
viru
segment
genom
three
genera
known
b
c
group
differ
core
protein
influenza
b
common
strongli
associ
epidem
histor
therapi
influenza
infect
amantidin
rimantidin
inhibit
viral
entri
cell
target
protein
influenza
viru
recent
treatment
option
influenza
b
expand
includ
neuraminidas
inhibitor
zanamivir
relenza
tm
oseltamivir
tamiflu
tm
neuraminidas
promot
influenza
viru
releas
infect
cell
facilit
viru
spread
within
respiratori
tract
inhibitor
block
replic
influenza
b
virus
caus
fewer
side
effect
less
potenti
select
resist
variant
inhibitor
earli
treatment
either
drug
reduc
sever
durat
influenza
symptom
associ
complic
hayden
et
al
treanor
et
al
makela
et
al
monto
et
al
kashiwagi
et
al
antivir
efficaci
zanamivir
monitor
analysi
rate
declin
upper
airway
viral
load
determin
time
cours
treatment
viral
titr
present
patient
sampl
histor
determin
cultureenhanc
enzymelink
immunosorb
assay
ceelisa
plaqu
assay
describ
barnett
et
al
sinc
method
reli
abil
clinic
isol
replic
cell
cultur
may
possibl
quantifi
virus
replic
ineffici
fail
produc
cytopath
effect
cell
cultur
fluorogen
realtim
pcrbase
techniqu
detect
quantifi
influenza
b
viru
rna
develop
serv
altern
assay
depend
upon
replic
effici
viru
cell
cultur
capac
viru
form
plaqu
sensit
specif
monoclon
antibodi
real
time
qpcr
modifi
form
pcr
measur
increas
pcr
product
time
reaction
exploit
nucleas
activ
taq
polymeras
cleav
sequenc
specif
fluoresc
label
probe
sometim
known
taqman
pcr
holland
et
al
lee
et
al
livak
et
al
purpos
studi
characteris
real
time
qpcr
assay
crossvalid
ceelisa
method
use
laboratori
strain
viru
two
panel
clinic
isol
ceelisa
detect
nucleoprotein
infecti
viru
particl
express
tcid
ml
wherea
real
time
qpcr
assay
detect
total
number
matrix
protein
gene
viral
nucleic
acid
infecti
noninfecti
given
differ
two
method
relationship
viral
load
determin
ceelisa
method
real
time
qpcr
assay
rel
sensit
assay
determin
laboratori
grown
stock
titr
pfuml
respect
dilut
fold
fold
step
pool
viru
transport
medium
give
valid
control
sampl
nomin
concentr
influenza
influenza
b
high
medium
low
titr
approxim
concentr
valid
control
sampl
pfuml
influenza
pfuml
respect
viru
transport
medium
obtain
virocult
swab
medic
wire
equip
co
corsham
wiltshir
england
serial
fold
dilut
prepar
phosphatebuff
salin
pb
panel
consist
throat
swab
sampl
taken
within
andor
day
symptom
influenza
onset
patient
influenza
origin
diagnos
patient
test
nasal
swab
taken
patient
day
posit
result
diagnost
multiplex
pcr
describ
stockton
et
al
andor
viru
cultur
obtain
day
sampl
panel
b
consist
throat
swab
patient
symptom
upper
airway
infect
diagnos
posit
influenza
throat
swab
taken
day
onset
influenzalik
symptom
inform
consent
obtain
collect
sampl
natur
possibl
consequ
studi
fulli
explain
viru
detect
cell
cultur
ceelisa
perform
describ
barnett
et
al
viral
rna
isol
l
sampl
use
qiaamp
viral
rna
kit
cdna
synthesi
carri
use
omniscript
tm
kit
accord
manufactur
instruct
qiagen
hilden
germani
reaction
prime
mixtur
random
hexam
primer
specif
highli
conserv
region
matrix
protein
gene
tct
aac
cga
ggt
cga
aac
gta
influenza
tca
tgg
cct
tct
gct
att
tc
influenza
b
incub
c
min
heat
c
min
cool
c
thermal
cycler
appli
biosystem
foster
citi
ca
usa
twenti
tempor
spatial
diverg
influenza
ten
ten
influenza
b
matrix
protein
gene
sequenc
retriev
public
databas
sinc
insuffici
homolog
matrix
protein
gene
sequenc
two
genera
align
separ
use
megalign
within
lasergen
softwar
packag
dnastar
region
homolog
identifi
primerprob
set
along
primer
revers
transcript
design
region
primer
express
softwar
use
verifi
select
primer
probe
sequenc
appli
biosystem
primer
sensea
aag
acc
aat
cct
gtc
acc
tct
ga
antisensea
caa
agc
gtc
tac
gct
gca
gtc
c
amplifi
pair
fragment
gene
influenza
influenza
specif
probe
fam
ttt
gtg
ttc
acg
ctc
acc
gt
tamra
anneal
part
sequenc
amplifi
two
primer
primer
senseb
gag
aca
caa
ttg
cct
acc
tgc
tt
antisenseb
ttc
ttt
ccc
acc
gaa
cca
ac
amplifi
pair
fragment
gene
influenza
b
probe
specif
influenza
b
aga
aga
tgg
aga
agg
caa
agc
aga
act
agc
tamra
similarli
anneal
part
sequenc
amplifi
two
primer
probe
primer
obtain
appli
biosystem
pcr
consist
final
concentr
univers
master
mix
appli
biosystem
nm
primer
nm
influenza
probe
nm
influenza
b
probe
plu
l
target
cdna
made
volum
l
nucleas
free
water
promega
corp
madison
usa
ung
treatment
c
min
ung
inactivationamplitaq
gold
activ
c
min
cdna
amplifi
two
step
cycl
c
denatur
dna
min
c
primer
anneal
extens
qpcr
reaction
carri
well
microtitr
plate
real
time
quantit
pcr
amplif
measur
real
time
mode
use
appli
biosystem
data
gather
analys
viral
load
calcul
use
sequenc
detect
system
microsoft
excel
microsoft
corp
redmond
washington
use
export
manipul
viral
load
data
copi
number
viral
cdna
copiesml
viru
transport
medium
determin
influenza
b
comparison
serial
dilut
plasmid
standard
known
concentr
includ
well
plate
least
four
calibr
standard
contain
known
copi
number
viru
includ
plate
indic
chang
effici
viral
rna
extract
rt
reaction
separ
plasmid
contain
influenza
b
deriv
insert
includ
real
time
qpcr
assay
amplicon
construct
ligat
pcr
amplifi
matrix
gene
fragment
pcrii
accord
instruct
ta
clone
kit
dual
promotor
invitrogen
groningen
netherland
clone
influenza
fragment
compris
entir
protein
gene
obtain
rtpcr
stock
clone
influenza
b
fragment
bp
region
influenza
b
isol
amplifi
primer
agg
aac
gct
ctg
tgc
ttt
gtg
tct
ttg
gct
tgg
att
tct
plasmid
dna
amplifi
e
coli
strain
accord
manufactur
protocol
purifi
use
qiagen
plasmid
midi
kit
qiagen
plasmid
insert
dna
sequenc
verifi
sequenc
direct
use
dyelabel
dideoxytermin
cycl
sequenc
sequenc
analys
use
abi
model
appli
biosystem
data
assembl
seqman
dnastar
manual
proof
read
align
repres
publish
sequenc
genbank
access
concentr
puriti
plasmid
dna
calcul
measur
dilut
te
buffer
ph
plasmid
dna
serial
dilut
tenfold
te
buffer
ph
plasmid
copiesl
use
real
time
pcr
degre
homolog
publicli
avail
sequenc
primer
probe
sequenc
compar
use
basic
local
align
search
tool
blastn
basic
blast
n
altschul
et
al
plasmid
vector
pcrii
contain
part
genom
respiratori
virus
respiratori
syncyti
viru
parainfluenza
iii
human
rhinoviru
coronaviru
adenoviru
clone
accord
manufactur
instruct
invitrogen
plasmid
purifi
use
plasmid
mini
kit
qiagen
dilut
copiesl
cdna
gener
stock
virus
human
rna
use
random
hexam
prepar
use
omniscript
tm
kit
qiagen
sybr
green
assay
perform
replac
univers
master
mix
sybr
green
pcr
master
mix
contain
sybr
green
dye
appli
biosystem
pcr
mix
consist
final
concentr
sybr
green
master
mix
appli
biosystem
primer
describ
optimis
nm
l
target
cdna
pcr
reaction
volum
made
l
nucleas
free
water
promega
corp
cycl
condit
ident
describ
serial
fold
dilut
use
establish
relationship
influenza
viral
load
determin
ceelisa
method
real
time
pcr
assay
ie
tcid
ml
viral
cdna
copi
rel
sensit
assay
fig
confirm
real
time
qpcr
consist
sensit
show
broader
dynam
rang
three
log
copiesml
correspond
tcid
ml
pfuml
defin
assay
system
sinc
stock
viral
isol
requir
subsequ
drugsuscept
analys
determin
minimum
number
influenza
viru
genom
copi
sampl
determin
real
time
qpcr
requir
gener
stock
infecti
viru
littl
differ
differ
viral
strain
test
term
minimum
viral
load
express
log
viral
rna
copiesml
detect
ceelisa
assay
viral
load
measur
log
copiesml
log
tcid
ml
ashangdong
log
copiesml
log
tcid
ml
ataiwan
subtyp
vrna
log
copiesml
log
tcid
ml
blisbon
howev
differ
minimum
number
copi
influenza
viru
genom
requir
gener
stock
infecti
viru
minimum
genom
copi
number
virus
requir
gener
viru
stock
l
viru
dilut
use
genom
copi
respect
sensit
agreement
real
time
pcr
ceelisa
assess
blind
test
throat
swab
sampl
panel
includ
patient
confirm
influenza
tabl
depict
conting
tabl
qualit
quantit
result
measur
real
time
pcr
comparison
ceelisa
posit
sampl
detect
ceelisa
real
time
pcr
neg
sampl
method
real
time
pcr
detect
addit
posit
fail
detect
six
posit
previous
detect
ceelisa
fisher
exact
test
appli
conting
tabl
check
whether
proport
posit
neg
method
ceelisa
result
differ
significantli
real
time
qpcr
p
sampl
posit
ceelisa
real
time
pcr
mean
viral
load
log
copiesml
compar
log
copiesml
posit
real
time
pcr
alon
signific
posit
real
time
pcr
ceelisa
mean
tcid
ml
compar
tcid
ml
posit
ceelisa
alon
signific
addit
sampl
posit
influenza
real
time
qpcr
limit
quantif
could
includ
analysi
compar
addit
posit
limit
quantif
group
posit
test
common
data
gener
laboratori
strain
viru
suggest
real
time
pcr
assay
sensit
ceelisa
method
fig
depict
comparison
influenza
quantif
throat
swab
real
time
qpcr
ceelisa
use
mean
viral
load
gener
real
time
qpcr
express
log
vrna
copiesml
viru
transport
medium
blq
limit
quantif
real
time
qpcr
ceelisa
result
given
mean
tcid
ml
subset
patient
panel
b
diagnos
influenza
n
influenza
b
n
posit
drop
viral
load
time
demonstr
use
method
decreas
viral
load
gener
less
rapid
measur
real
time
qpcr
abil
real
time
qpcr
assay
differenti
influenza
b
infect
investig
compar
influenza
viru
type
obtain
suggest
diagnost
multiplex
pcr
viru
cultur
ceelisa
concord
influenza
viru
type
three
assay
blastn
search
primer
probe
sequenc
suggest
primer
probe
sequenc
genu
specif
oligonucleotid
design
anneal
influenza
homolog
sequenc
broad
rang
viru
subtyp
includ
isol
report
sever
decad
similarli
oligonucleotid
design
anneal
influenza
b
also
homolog
sequenc
broad
rang
influenza
b
isol
report
number
year
specif
real
time
qpcr
assay
determin
experiment
spike
influenza
b
real
time
pcr
reaction
individu
copi
pcrii
plasmid
invitrogen
contain
part
genom
respiratori
virus
addit
stock
cdna
gener
stock
virus
human
rna
use
random
hexam
ad
individu
pcr
reaction
specif
method
also
assess
inclus
blank
sampl
assay
check
nonspecif
reaction
compon
specif
real
time
pcr
assay
confirm
neg
read
given
blank
sampl
inappropri
target
includ
human
viral
cdna
plasmid
contain
sequenc
respiratori
virus
posit
read
gener
five
laboratori
grown
strain
influenza
furthermor
assay
differenti
influenza
b
crossreact
allow
multiplex
two
assay
specif
primer
test
compar
perform
probebas
assay
nonspecif
real
time
report
system
involv
substitut
influenza
viru
specif
label
hydrolysi
probe
sybr
green
dye
fluoresc
bound
non
specif
doubl
strand
dna
repeat
assay
use
pcr
primer
real
time
mode
throat
swab
panel
b
test
use
probe
base
sybr
green
assay
twentyfour
sampl
influenza
posit
sampl
neg
system
four
influenza
posit
sampl
previous
detect
probebas
assay
detect
sybr
green
assay
two
posit
detect
sybr
green
fig
percentag
coeffici
variat
dynam
rang
real
time
qpcr
assay
denot
limit
detect
limit
quantif
say
detect
previou
probe
assay
fig
depict
comparison
viral
load
measur
obtain
use
probebas
assay
obtain
use
sybr
green
assay
although
relationship
two
assay
present
sybr
green
assay
consist
report
higher
copi
number
less
agreement
two
assay
low
copi
number
dilut
valid
control
viru
stock
use
determin
variabl
dynam
rang
limit
quantif
real
time
qpcr
assay
real
time
qpcr
assay
variabl
express
mean
coeffici
variat
determin
assess
agreement
measur
nomin
concentr
serial
dilut
laboratori
strain
influenza
b
virus
design
valid
control
sampl
analys
replic
three
six
separ
occas
fig
precis
method
determin
assess
agreement
replic
measur
valid
control
sampl
transform
raw
data
common
logarithm
perform
analysi
varianc
anova
lower
upper
limit
quantif
defin
valid
control
sampl
concentr
possess
accept
precis
lowest
amount
influenza
vrna
copiesml
present
sampl
coeffici
variat
exceed
lower
limit
quantit
log
copiesml
ten
copiespcr
reaction
obtain
linear
rang
assay
threshold
cycl
laboratori
strain
dilut
plot
correspond
initi
templat
concentr
coeffici
regress
graph
consist
greater
experi
carri
result
indic
good
correl
rang
copiespcr
reaction
log
copiesml
linear
rang
assay
least
seven
order
magnitud
possibl
verifi
upper
end
dynam
rang
sinc
sampl
high
viral
load
rare
real
time
qpcr
assay
use
measur
influenza
viral
load
clinic
sampl
sampl
contain
influenza
rna
quantifi
without
need
sampl
dilut
concentr
interassay
coeffici
variat
rang
dynam
rang
increas
viral
load
log
vrna
copiesml
interassay
coeffici
variat
express
variat
within
differ
experi
eg
carri
differ
day
use
differ
equip
differ
batch
reagent
intraassay
coeffici
variat
rang
approxim
measur
rang
concentr
overal
method
cv
order
individu
cv
greater
low
concentr
viru
variabl
introduc
use
differ
batch
reagent
instrument
use
cycl
monitor
real
time
qpcr
reaction
thermal
cycler
use
make
cdna
exampl
geneamp
appli
biosystem
also
investig
use
valid
control
sampl
differ
viral
load
result
gener
result
use
differ
instrument
perform
monitor
real
time
qpcr
differ
thermal
cycler
prepar
cdna
geneamp
differ
batch
reagent
assay
perform
also
affect
qualiti
sampl
process
intermedi
determin
length
time
quantiti
viru
sampl
store
viru
transport
medium
might
still
meaning
interpret
stabil
valid
control
stock
virus
dilut
transport
medium
replic
six
store
c
assess
monitor
viru
copi
number
measur
real
time
qpcr
month
period
viral
rna
within
influenza
influenza
b
particl
store
c
viru
transport
medium
deterior
significantli
measur
signific
deviat
copi
number
measur
initi
almost
month
period
viral
rna
associ
viru
particl
concentr
test
stabl
viru
transport
medium
store
c
least
day
unpublish
observ
indic
viru
store
way
may
stabl
much
longer
period
howev
effect
viabil
viru
known
effect
long
term
storag
qualiti
cdna
gener
clinic
sampl
determin
real
time
qpcr
test
cdna
prepar
throat
swab
sampl
panel
b
result
obtain
use
freshli
prepar
cdna
compar
result
obtain
cdna
storag
c
month
signific
differ
result
obtain
use
freshli
made
influenza
b
cdna
test
storag
c
month
sampl
test
posit
influenza
b
retest
posit
sampl
origin
neg
remain
neg
influenza
cdna
test
origin
posit
remain
quantifi
origin
neg
remain
neg
two
sampl
limit
quantit
quantit
differ
within
cv
limit
describ
method
effect
freez
thaw
influenza
viru
viru
transport
medium
viral
rna
cdna
determin
use
real
time
qpcr
assay
measur
copi
number
viru
valid
control
sampl
medium
concentr
valid
control
sampl
test
replic
three
four
freezethaw
cycl
c
ambient
temperatur
influenza
influenza
b
concentr
five
freezethaw
cycl
significantli
differ
concentr
measur
prior
freez
sampl
variat
viral
load
within
cv
limit
describ
real
time
qpcr
assay
use
measur
viral
load
influenza
b
viral
rna
found
give
trend
decreas
viral
load
number
freezethaw
cycl
becam
signific
declin
viral
load
measur
initi
four
freezethaw
cycl
p
viral
cdna
return
similar
viral
load
valu
four
freezethaw
cycl
freshli
prepar
cdna
establish
shelf
life
work
stock
plasmid
use
assay
standard
stabil
c
assess
compar
threshold
cycl
ct
valu
gener
real
time
qpcr
assay
duplic
fold
dilut
span
copiespcr
reaction
freshli
prepar
solut
month
interv
threshold
cycl
ct
valu
valu
gener
real
time
pcr
pcr
cycl
statist
significantli
increas
normalis
fluoresc
intens
first
detect
similarli
stabil
high
concentr
plasmid
copiesl
stock
store
c
assess
month
period
monitor
ct
valu
obtain
dilut
copiesl
test
real
time
qpcr
assay
analyt
solut
plasmid
contain
insert
influenza
influenza
b
genom
use
standard
rel
stabl
well
seal
tube
store
c
least
day
result
obtain
real
time
pcr
reaction
perform
use
valid
control
sampl
triplic
prepar
h
advanc
pcr
store
c
compar
freshli
prepar
reaction
determin
possibl
prepar
store
pcr
reaction
advanc
result
obtain
real
time
qpcr
valid
control
sampl
reaction
prepar
h
advanc
pcr
store
c
significantli
differ
freshli
assembl
reaction
suggest
possibl
set
reaction
advanc
perform
qpcr
sensit
quantit
assay
describ
critic
high
throughput
monitor
patient
sampl
sinc
one
way
monitor
antivir
efficaci
neuraminidas
inhibitor
analys
rate
viral
load
declin
upper
airway
time
cours
treatment
real
time
quantit
pcr
assay
describ
appli
determin
antivir
activ
inhal
zanamivir
treatment
natur
acquir
influenza
militari
recruit
live
residenti
unit
signific
increas
rate
viral
load
reduct
shown
zanamivir
therapi
commenc
compar
placebo
puhakka
et
al
assay
use
histor
semiquantit
depend
upon
growth
infecti
viru
plaqu
assay
upon
capac
viru
form
plaqu
variat
minimum
number
influenza
viru
copi
differ
viru
subtyp
requir
gener
stock
infecti
viru
may
due
differ
adapt
cell
cultur
variat
level
noninfecti
viru
particl
laboratori
cultur
viru
strain
success
assay
ceelisa
also
depend
avail
monoclon
antibodi
high
sensit
specif
detect
viral
nucleoprotein
evid
suggest
result
diagnost
test
depend
upon
detect
nucleoprotein
enzym
conjug
monoclon
antibodi
directigen
tm
flua
test
beckton
dickinson
cockeysvil
maryland
us
affect
freez
thaw
specimen
prior
test
waner
et
al
nucleic
acid
base
real
time
pcr
assay
affect
five
sampl
freezethaw
event
suggest
even
though
influenza
rna
viru
method
base
upon
amplif
short
segment
viral
rna
robust
decreas
viral
load
gener
less
rapid
measur
real
time
qpcr
measur
ceelisa
probabl
due
slower
decay
rate
viral
nucleic
acid
measur
pcr
rel
infecti
viru
employ
real
time
pcr
technolog
purpos
screen
patient
particip
clinic
trial
neuraminidas
inhibitor
sever
advantag
inclus
extern
standard
curv
reliabl
quantif
influenza
cdna
assay
linear
seven
order
magnitud
elimin
need
sampl
dilut
minimis
sampl
handl
associ
increas
variabl
limit
data
shown
suggest
sampl
higher
viral
load
accur
quantit
result
obtain
extrapol
standard
curv
report
low
viral
load
quantiti
interpret
caution
particularli
small
magnitud
viral
load
chang
low
viral
load
chanc
experienc
crosscontamin
henc
fals
posit
result
low
need
post
pcr
sampl
handl
remov
sinc
detect
pcr
product
occur
onlin
realtim
pcr
amplif
real
time
qpcr
reaction
set
advanc
cycl
allow
process
batch
addit
appropri
archiv
sampl
cdna
prime
random
hexam
appropri
specif
primer
retest
use
real
time
qpcr
assay
depend
infect
viru
sinc
intern
standard
avail
quantit
result
express
viral
rna
copiesml
swab
transport
medium
lowest
amount
influenza
viru
cdna
quantifi
assay
log
copiesml
assay
set
speed
throughput
prioriti
like
sensit
limit
quantif
could
achiev
increas
quantiti
materi
extract
concentr
limit
quantif
coeffici
variat
repeat
test
becom
unaccept
larg
actual
quantiti
difficult
interpret
case
pcr
base
assay
probabl
rather
sampl
qualiti
variat
predomin
caus
variabl
low
copi
number
de
vri
et
al
theoret
uncertainti
measur
made
quantit
pcr
model
theoret
variabl
viral
load
ten
copiespcr
reaction
log
copiesml
calcul
greater
even
assum
optim
pcr
effici
exclud
variabl
peccoud
jacob
result
intraand
interassay
precis
indic
assay
reproduc
even
differ
batch
reagent
differ
thermal
cycler
instrument
use
addit
factor
affect
real
time
qpcr
assay
reproduc
suscept
viru
process
intermedi
assay
rna
cdna
degrad
time
storag
repeat
freez
thaw
influenza
viru
store
c
cdna
stock
made
viru
kept
c
stabl
long
period
sever
freezethaw
cycl
suggest
possibl
appli
real
time
qpcr
assay
quantifi
influenza
appropri
store
archiv
sampl
appropri
prime
cdna
stock
howev
sampl
viral
load
limit
quantit
may
vulner
degrad
data
suggest
viral
load
test
feasibl
thaw
retest
throat
swab
sampl
store
viru
transport
medium
five
time
sampl
intend
use
real
time
qpcr
store
collect
viru
transport
medium
process
make
cdna
longterm
storag
futur
analysi
like
sampl
revisit
molecular
studi
store
nake
rna
although
viral
rna
concentr
test
rel
stabl
store
c
affect
freez
thaw
event
three
influenza
strain
test
real
time
pcr
assay
compar
ceelisa
viru
cultur
result
good
agreement
conclud
assay
compar
result
obtain
laboratori
howev
real
time
pcr
assay
fold
sensit
viru
infect
assay
ceelisa
potenti
use
maxim
sensit
requir
analysi
influenza
viral
load
requir
clinic
trial
similarli
real
time
qpcr
assay
appear
sensit
appli
clinic
sampl
clinic
trial
zanamivir
requir
quantifi
viru
throat
main
site
action
drug
well
nose
titr
may
higher
therefor
use
real
time
pcr
assay
allow
quantit
viral
load
lower
concentr
viru
may
neg
ceelisa
method
howev
distinct
two
assay
ceelisa
detect
infecti
viru
wherea
pcr
assay
includ
real
time
qpcr
assay
detect
infecti
noninfecti
viru
therefor
detect
quantit
viral
nucleic
acid
real
time
pcr
may
reflect
presenc
viru
unabl
produc
infect
product
noninfecti
viru
particl
known
von
magnu
effect
particularli
common
laboratori
strain
viru
convers
possibl
viru
concentr
limit
detect
real
time
qpcr
would
abl
infect
cell
produc
posit
result
cultur
base
system
given
high
degre
sequenc
conserv
site
bind
primer
probe
like
assay
could
appli
detect
wide
varieti
differ
human
anim
strain
influenza
three
differ
haemaglutinin
two
neuraminidas
subtyp
account
virtual
human
infect
hayden
pales
sequenc
subtyp
found
human
includ
strain
recov
outbreak
hong
kong
claa
et
al
align
probe
primer
sequenc
influenza
unlik
assay
describ
publish
assay
van
elden
et
al
schweiger
et
al
unlik
quantifi
accur
sensit
detect
isol
due
misalign
least
one
four
nucleotid
chang
probe
sequenc
highlight
need
regular
review
primer
probe
sequenc
use
diagnost
quantif
virus
subject
genet
drift
robust
assay
primer
confirm
similar
qualit
result
obtain
sybr
green
assay
although
sybr
green
assay
tend
report
slightli
higher
viral
load
valu
use
real
time
qpcr
assay
describ
routin
set
throat
swab
screen
confirm
allow
rapid
throughput
high
number
sampl
gener
reliabl
quantit
result
greater
sensit
achiev
previou
commonli
use
influenza
assay
largescal
screen
identif
influenza
viru
use
real
time
qpcr
carri
part
develop
zanamivir
new
approach
also
help
knowledg
dynam
influenza
viru
infect
effect
novel
therapi
influenza
viral
load
